Balancing Innovation and Access

Can We Lower Drug Prices in a Pandemic?

FRIDAY, APRIL 30, 2021
12:00–1:00 p.m. ET

PRESENTED BY
Stacie Dusetzina, PhD

ABOUT
THE SPEAKER

STACIE DUSETZINA, PhD

Dr. Stacie Dusetzina is an Associate Professor in the Department of Health Policy and an Ingram Associate Professor of cancer research at Vanderbilt University School of Medicine. She is a health services researcher focusing on the intersection between health policy, epidemiology, and economics related to prescription drugs.

Dr. Dusetzina’s work has contributed to the evidence base for the role of drug costs on patient access to care and policy changes that might improve patient access to high-priced drugs. To date she has authored or co-authored over 150 peer reviewed studies related to health policy and access to and use of prescription drugs.

Dr. Dusetzina has been recognized for her work at a national level, including being an invited participant for two working group meetings on “Patient Access to Affordable Cancer Drugs,” hosted by the President’s Cancer Panel, and being selected to co-author a National Academies of Sciences, Engineering and Medicine report on the same topic. Her research has also been broadly covered by NPR, New York Times, Reuters, Washington Post, STAT News, ABC News, and Wall Street Journal.
This annual lecture brings together policymakers, corporate leaders, researchers, students, and faculty for substantive discussions on leading health policy issues.

ABOUT CHARLES C. LEIGHTON, MD

Since 1994, this annual lecture has honored the memory of the late Charles C. Leighton, MD (1938–93), through a generous endowment from the Merck Company Foundation. Dr. Leighton was Senior Vice President of Administration, Planning, and Science Policy at Merck Research Laboratories for nearly three decades, where he was responsible for the international regulatory approval of drugs for Merck and Co., Inc.

Dr. Leighton distinguished himself through his leadership and vision, and his gift for galvanizing and harmonizing scientists, company management, and government officials behind a common goal—delivering breakthrough medicines and vaccines to the people who need them around the world. Dr. Leighton was widely regarded in making regulatory affairs an integral part of every drug company’s operation and product development strategy, becoming the best in the world in his field and a model for other companies and regulatory agencies to emulate.